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chemotherapy agent paclitaxel and could induce tumor is that mAbs can also work by binding to cell surface
molecules that are involved in life, death, and growthregressions in women with metastatic breast cancer
who had failed first-line therapies. A wise clinical investi- decisions of cancer cells. Molecules such as CD20 and
HER2/neu provide signals for growth and survival ofgator told me 15 years ago that mAbs would fit best
when combined with chemotherapy (prescient remarks cancer cells, and altering these signals may be neces-
sary for clinical efficacy of the respective mAbs. It will beconsidering the Herceptin story). Treatment of high-risk
patients with colorectal carcinoma using the mAb 17-1A important to sort out immune and inflammatory effects
versus direct biologic effects on receptors, especiallyas an adjuvant treatment has shown improved survival in
one randomized study (Riethmuller, 1998), and these as we add on cytotoxic molecules such as nuclides or
results are being tested in a follow-up clinical trial. In toxins. But this is when clinical research is at its best.
noncancer diseases, mAbs were being approved for Clinical observations are wonderful phenomena that
inhibiting transplantation rejection, decreasing risk of form the basis for addressing scientific questions. And
myocardial infarction and death after balloon angio- what could be a better question than how mAbs cause
plasty, and treatment of inflammatory bowel disease tumors to regress or disappear in people.
(with possible application to other inflammatory dis-
eases like rheumatoid arthritis). Things were definitely
looking up. Alan N. Houghton
The volume Monoclonal Antibody-Based Therapy of Memorial Sloan-Kettering Cancer Center
Cancer, edited by Michael L. Grossbard, provides a use- New York, New York 10021
ful snapshot of mAbs for cancer treatment in the late
1990s, reflecting cautious optimism and in some cases
Referencesdownright enthusiasm. It is a compilation of chapters
written by laboratory researchers and clinicians, with an
Houghton, A.N., Mintzer, D., Cordon-Cardo, C., Welt, S., Fliegel, B.,emphasis on preclinical and clinical development. The
Vadham, S., Carswell, E., Melamed, M.R., Oettgen, H.F., and Old,book opens with chapters on preclinical development
L.J. (1985). Proc. Natl. Acad. Sci. USA 82, 1242±1246.
of toxin±mAb conjugates and a wonderful review by
Kohler, G., and Milstein, C. (1975). Nature 256, 495±497.
Rakesh Jain of tumor physiology and broad issues in-
McLaughlin, P., Grillo-Lopez, A.J., Link, B.K., Levy, R., Cruczman,
volved in targeting therapies to tumors. The authors then M.S., Williams, M.E., Heyman, M.R., Bence-Bruckler, I., White, C.A.,
cover updates of mAb treatment of specific cancers Cabanillas, F., et al. (1998). J. Clin. Oncol. 16, 2825±2833.
including lymphomas, leukemia, and various solid tu- Miller, R.A., Maloney, D.G., Warnke, R., and Levy, R. (1982). N. Engl.
mors. There is an emphasis on treatment of lymphoma, J. Med. 306, 517±522.
with six chapters devoted to this topic. This reflects the Riethmuller, G., Holz, E., Schlimok, G., Schmiegel, W., Raab, R.,
relative importance of clinical studies of lymphomas and Hoffken, K., Gruber, R., Funke, I., Pichlmaier, H., Hirsch, H., et al.
(1998). J. Clin. Oncol. 16, 1788±1794.the lessons learned from these clinical trials.
Two chapters cover the use of mAbs in transplanta- Scheinberg, D.A., and Houghton, A.N. (1987). Oncology 1, 31±40.
tion, including treatment of graft-versus-host disease Vadhan-Raj, S., Cordon-Cardo, C., Carswell, E., Mintzer, D., Dantis,
L., Duteau, C., Templeton, M.A., Oettgen, H.F., Old, L.J., andand a thorough discussion of processing and purging
Houghton, A.N. (1988). J. Clin. Oncol. 6, 1636±1648.of hematopoietic cells. These are two areas where mAb
will certainly have a clinical impact. The section on treat-
ment of solid tumors begins with an overview of the
subject, mentioning the difficulties in targeting mAb to
solid tumors. This overview is followed by chapters on Asthma and the New Millennium
mAb treatment of breast, lung, and colorectal carcinoma
and melanoma. In particular, the chapter on lung cancer
Asthma: Basic Mechanisms and Clinical Management,by John Mendelsohn and colleagues explores the strat-
Third Editionegy of using mAbs against growth factor receptors, an
Edited by Peter J. Barnes, Ian W. Rodger, and Neil C.area of great interest given the recent success of Her-
Thomsonceptin treatment.
San Diego, CA: Academic Press (1998). 942 pp. $150.00Overall, the greatest weight is given to toxin-based
therapies (for instance, the opening and closing chap-
Inflammatory Mechanisms in Asthmaters, and two of the six chapters on lymphoma), presum-
Edited by Stephen T. Holgate and William W. Busseably reflecting the editor's interests. The chapters on
New York: Marcel Dekker (1998). 962 pp. $235.00toxin±mAb conjugates are particularly strong and and
are authored by leaders in their respective fields. One
Asthma and Allergic Diseases: Physiology, Immuno-quibble is there is not much representation of nuclide-
pharmacology, and Treatmentbased or drug±conjugate mAb treatments.
Edited by Gianni Marone, K. Frank Austen, Stephen T.Upon reading this volume, it struck me how little we
Holgate, A. Barry Kay, and Lawrence M. Lichtensteinstill understand about biologic activities of mAbs in vivo
San Diego, CA: Academic Press (1998). 439 pp. $95.00as they approach their 25th birthday. Do we really know
how mAbs shrink tumors? The early clinical activity of
mAbs in solid tumors was presumably due to activation
Asthma has plagued humanity for millennia with re-and recruitment of immune and inflammatory compo-
corded references to wheezing in the Su Wen, the Yellownents such as lymphocytes, macrophages, and comple-
ment (Vadhan-Raj, 1988). Presently a popular paradigm Emperor of China's treatise on medicine and religion (ca.
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2600 BC). It remains a common disease today, affecting the bronchial mucosa nor the physiology of airflow ob-
struction seen in allergen treated wild-type animals (Bru-approximately 5% of the U.S. population, and its preva-
selle et al., Am. J. Respir. Cell Mol. Biol., 12, 254±259,lence has increased steadily over recent years (McFad-
1994). Interruption of IL-4 receptor signal transductionden and Smith, New Engl. J. Med. 327, 1928±1937, 1992).
by targeted disruption of STAT6 also results in an attenu-Affected patients suffer from episodes of wheezing,
ation of the bronchial allergic response (Akimoto et al.,cough and, dyspnea, often triggered by viral respiratory
J. Exp. Med., 187, 1537±1542, 1998).infections or allergen inhalation. Glucocorticoids remain
Discussions of asthma genetics in two of these collec-the cornerstone of asthma therapy and, while quite ef-
tions provide hints as to the inborn factors that mightfective, are limited by their multiple toxicities.
sway some of our airways toward IL-4 production andIt has long been appreciated that episodes of bron-
Th2 responses. William Cookson's concise but com-chial narrowing, which give rise to the acute exacerba-
plete review of this topic in Asthma and Allergic Diseasestions of asthma, result from acute smooth muscle con-
summarizes how sib pair analyses have revealed a link-striction, airway mucosal edema, and mucous secretion.
age between total IgE levels and chromosome 5q21±33.It is now clear that a more persistent inflammatory pro-
This region encodes not only IL-4 but a number of othercess, characterized by a mucosal infiltrate of eosinophils
cytokines with putative roles in allergy, including IL-3,and mononuclear cells, underlies these acute changes.
IL-5, IL-9, IL-13, and GM-CSF. An IL-4 allele with a singleIn most cases of asthma, recurrent exposure to airborne
base pair mutation at 2590 affecting NFAT-1 bindingallergens drives this state of chronic allergic inflamma-
and enhancing IL-4 transcription is associated with in-tion (Barnes, J. Respir. Dis. 15, S7±S18, 1994).
creased IgE levels and asthma (Rosenwasser et al., Clin.Three recently published volumes (Asthma: Basic
Exp. Allergy, 25 [Suppl. 2], 74±78, 1995). The chapterMechanisms and Clinical Management, Third Edition,
on genetics in Asthma: Basic Mechanisms and ClinicalBarnes, Rodger, and Thomson, eds.; Inflammatory
Management (Meijer, Bleecker and Postma, p. 35) alsoMechanisms in Asthma, Holgate and Busse, eds.; and
covers these areas well and includes additional excel-Asthma and Allergic Diseases, Marone, Austen, Holgate,
lent discussion of the genetics of bronchial hyperre-Kay, and Lichtenstein, eds.) provide an excellent over-
sponsiveness. Perhaps because of the timing of publica-view of the current understanding of this inflammatory
tion, neither review points out a recently reported linkageprocess. Together, they contain 119 reviews. Central
between atopy and a gain-of-function mutation of theareas such as genetics of asthma, T cell responses to
IL-4 receptor b chain that results in impaired binding ofallergen, eosinophil and mast cell biology, adhesion
the signal transduction inhibitor SHP-1 (Hershey et al.,molecules, antigen presentation, and the roles of pep-
N. Engl. J. Med. 337, 1720±1725, 1997).tide and lipid mediators receive extensive attention in
As emphasized in the excellent review of Costa, Galli,each book.
and Church in Inflammatory Mechanisms in AsthmaThese collections bear in common the central theme
(p. 111), development of Th2 responses in the allergen-that allergic airway inflammation arises in individuals
exposed respiratory mucosa may receive a potent boostwho, because of genetic predisposition or environmen-
from resident mast cells. These mucosal sentinels re-tal factors, mount T cell responses to inhaled allergens.
lease mediators of immediate hypersensitivity reactionsThe expansion of allergen-specific T cells with a Th2
upon cross-linking by antigen of IgE bound to high-phenotype (expressing IL-4 and IL-5) is critical to asthma
affinity receptors on their surface. A more critical rolepathogenesis (Mossman and Coffman, Annu. Rev. Im-
of these cells, however, may be the maintenance ofmunol., 7, 145±173, 1989). The host and environmental
the Th2 shift in states of repetitive low dose allergenfactors that promote the Th2 shift in allergic individuals
exposure. Preformed, allergen-specific IgE stimulates
are the subject of some of the best reviews in these
the transcription of Th2 cytokines including IL-4 in mast
collections.
cells, providing a powerful local amplification of the aller-
The cell biology of pulmonary dendritic cells, which
gic response.
are central to initiating the Th2 response, is particularly Establishing an effective Th2 response sets the stage
well covered in back-to-back chapters by Edgeworth, for the recruitment of inflammatory effector cells includ-
Lee, and Gant and by Holt and McWilliam in Inflamma- ing eosinophils. The biology of these cells and their
tory Mechanisms in Asthma (pp. 387 and 401). Induction inextricable link to the pathophysiology of the disease
of the Th2 response is preceded by allergen uptake by receive the most complete coverage (five consecutive
dendritic cells and their mobilization to local lymphoid chapters) in Inflammatory Mechanisms in Asthma. To-
tissue. The expansion and activation of these cells fol- gether, the reviews chronicle the life of an eosinophil
lowing allergen encounter and the importance of their beginning with differentiation from bone marrow precur-
ªaccessory moleculesº is covered in detail. At this level, sors (driven by IL-3, IL-5, and GM-CSF), followed by
by interference with the interaction of antigen-pre- P-selectin-mediated rolling along the endothelium of in-
senting cell B7 with T cell CD28/CTLA-4, using a soluble flamed tissues and, finally, binding to VCAM on vascular
CTLA-4-Ig fusion protein or anti-B7.2 antibodies, allergic endothelium via VLA-4.
sensitization can be blocked. Eosinophils continue their migration toward the site
Once effectively stimulated, Th2 cells rely upon the of inflammation under the guidance of chemoattractants
continued presence of IL-4 for their survival (Drazen et including leukotriene B4 and platelet activating factor,
al., J. Exp. Med., 183, 1±5, 1996). Mice with a targeted which are well covered in these reviews. Recently, in-
deletion of IL-4 have markedly impaired Th2 develop- tense interest has focused on various members of the
chemokine family of 8±10 kDa chemoattractant peptidesment and display neither the eosinophil infiltration of
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which, in our opinion, receive adequate coverage only We believe that one area which should have received
in Asthma and Allergic Diseases (p. 157). The two che- more attention in each of these collections is the extent
mokines with greatest eosinophil specificity are eotaxin to which murine models of the disease have recently
1 and eotaxin 2. Targeted deletion of eotaxin 1 leads to been characterized and used in conjunction with mice
decreased eosinophil migration to allergen-sensitized with targeted gene mutations to assess the contribu-
lung (Rothenberg et al., J. Exp. Med., 185, 785±790, tions of particular cytokines, lipid mediators, transcrip-
1997). Although eotaxin has multiple cellular sources, tion factors, and immunoglobulins to the Th1/Th2 bal-
including respiratory epithelium, monocytes, and eosin- ance and asthma pathogenesis.
ophils themselves, its enhanced production at sites of Overall, these books provide an outstanding review
allergic inflammation is completely dependent on T of the field. Asthma Basic Mechanisms and Clinical Man-
cells. agement is the most comprehensive and is the only one
Asthma Basic Mechanisms and Clinical Management, in the group to cover clinical issues in detail. We would
which is now in its third edition, is the most ambitious strongly recommend it for Clinician/Scientists and basic
in scope among the three books reviewed here and researchers requiring a complete overview of the area.
certainly the most comprehensive. The first half covers Inflammatory Mechanisms in Asthma provides an excel-
basic pathophysiology and cellular and molecular mech- lent collection of reviews on the cells and mediators of
anisms in asthma. This includes excellent reviews of asthma. Asthma and Allergic Diseases, while not com-
asthma genetics, pathology, and physiology as well as prehensive, includes a number of outstanding chapters
chapters on the critical cell types and mediators that on specific rapidly developing areas not covered by the
participate in pathogenesis. This is certainly an impres- other two books. The latter two books are best suited
sive collection and there are no major omissions. Per- for those active in the field and can also be strongly
haps one undesired consequence of this complete and recommended.
broad coverage is an apparent pressure for space. Some These volumes make it clear that a number of potential
areas receive short shrift relative to their critical roles approaches hold promise for the future understanding
in asthma pathogenesis or in consideration of the impor- and therapy of this disease. Leukotriene antagonists are
tance of recent advances in those fields. For instance already in mainstream use and inhibitors of IgE recep-
eosinophil biology is covered only briefly (10 pages) and tors and eosinophilopoiesis are far along in their devel-
the discussion of chemokines, a critical field which has opment. One can be optimistic that the day should not
exploded in recent years, is also quite limited and in-
be far off when we will better understand the genetic
cludes only scant references to the eotaxins and to
and environmental factors that predispose some of us
chemokine receptors.
toward the Th2 response underlying the disease, andThe entire second half is devoted to clinical aspects
that the new millennium will bear witness to strategiesof diagnosis and management, an area not dealt with
that inhibit the central causes of allergy.in any significant depth in either of the other collec-
tions. These chapters are very complete with particular
strength in coverage of the pharmacotherapy of asthma. Hans C. Oettgen, M.D., Ph.D. and Raif S. Geha, M.D.
Although excellent, and broad in scope, this section Division of Immunology
might have benefited from additional discussion of the Children's Hospital
masqueraders and complicators of asthma including
Harvard Medical School
allergic bronchopulmonary aspergillosis, sinusitis, and
Boston, Massachusetts 02115
rhinitis.
Inflammatory Mechanisms in Asthma has a narrower
focus, devoting all of its 40 chapters to reviews of the
cellular and molecular mechanisms that drive allergic
airway inflammation. It has great depth in some areas, No Guts, No Glory: Mucosal Immunity
particularly, as mentioned above, eosinophil and den- Comes of Agedritic cell biology. There are some holes though, includ-
ing the absence of a chapter on chemokines.
Mucosal T CellsAsthma and Allergic Diseases contains the presenta-
Edited by Thomas T. MacDonaldtions of the Fifth International Conference on Asthma
Basel: Karger (1998). 242 pp. $208.75and Allergic Diseases (Ischia, Italy, 1997). It is the brief-
est of the books and the reviews are focused primarily
on basic mechanisms in allergic inflammation without
Mucosal immunology is the study of the structure andany attention to clinical issues. As would be expected
function of the immune system at the precarious inter-for a meeting report, it offers somewhat spotty coverage
face between the outside world and our inner biologicalof this huge area, and it lacks the unifying overviews of
selves. In the past ten years this field has enjoyed re-asthmatic pathology and pathophysiology that serve to
newed life due in part to the realization by immunologistsbind together the other two books. Nevertheless, it pro-
that this is where the action is. Mucosal surfaces arevides in-depth reviews of some of the ªhotº areas in the
where the vast majority of pathogens enter the host,field, including a nice overview of the chemokines as
and the prominence of HIV as one of these intruders haswell as excellent reviews on IgE receptors, the mast cell
focused considerable attention on mucosal immunity.inhibitory receptor GP-49, and the use of antisense and
Additionally, new immunological tools have been broughtDNA immunization strategies to modulate airways re-
sponses to allergens. to bear on inflammatory bowel diseases (IBDs). Couple
